🐦 推特Wall St EngineCodex · 实盘不做把握 5/10
北京时间·🕒 发布 18:09:17时区推断·⟳ 抓取 18:09:17·⚡ 决策 07-23 18:11:01 +1m44s·96.0 天前
赛默飞世尔公布2026年二季度业绩，收入和调整后EPS小幅好于预期
赛默飞世尔二季度收入119.9亿美元、调整后EPS 6.03美元，均高于市场预期，经营层面是正向信息。
📄 原文Wall St Engine@wallstengine↗ 原文
THERMO FISHER SCIENTIFIC $TMO Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $11.99B (Est. $11.7B) 🟢; +10% YoY 🔹 Adj. EPS: $6.03…
不做 赛默飞世尔（TMO.US）
排期内财报温和超预期，但缺少全年指引上修或市值级新增增量；盘前追开盘容易高开低走，当前不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司提前公告将在2026-07-23盘前发布二季度业绩并于08:30 ET召开电话会，披露日程不是突发。
- 社交账号在美股盘前快速转发TMO二季度收入、EPS和分部收入数据，属于财报数字扩散。市场反应:事件发生时美股仍未开盘，无法确认连续交易反应。
- 公司安排同日08:30 ET电话会讨论财务表现和预期，关键指引信息需等待电话会完整口径。
关键理由
- 赛默飞世尔二季度收入119.9亿美元、调整后EPS 6.03美元，均高于市场预期，经营层面是正向信息。
- 这是排期内美股盘前财报披露，收入超预期约2.5%、EPS超预期约5.6%，但信号未给出全年指引上修或市值级新增订单。
- TMO为大市值成熟医疗工具公司，单季温和beat更像预期校准，短线追多需要更强的指引 surprise。
主要风险
- 财报电话会尚未结束，若管理层上调全年指引或给出强订单恢复信号，可能需要由新信号重新评估。
- 排期财报日容易出现盘前高开后回落，当前缺少真实盘前成交和指引增量，追开盘性价比不足。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-23 · 影响 weakens
截至当前检索，信号正文和可见官方日程未显示全年指引上修或新增订单金额，温和beat不足以确认强追多edge。
检索:Thermo Fisher Q2 2026 guidance raise earnings call 2026 outlook 原文 ↗
原文全文
展开原文 · 857 字
THERMO FISHER SCIENTIFIC $TMO Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $11.99B (Est. $11.7B) 🟢; +10% YoY
🔹 Adj. EPS: $6.03 (Est. $5.71) 🟢; +13% YoY
🔹 Organic Revenue Growth: 5%
Other Q2 Metrics:
🔹 Organic Revenue Growth: 5%
🔹 GAAP Operating Margin: 17.4%; +50 bps YoY
🔹 Adjusted Operating Margin: 22.8%; +90 bps YoY
🔹 Free Cash Flow: $1.68B
Segment Net Revenue:
🔹 Life Sciences Solutions: $2.8B
🔹 Analytical Instruments: $1.8B
🔹 Specialty Diagnostics: $1.2B
🔹 Laboratory Products and Biopharma Services: $6.7B
Comments:
🔸 “Our end markets continue to strengthen and we're making great progress enhancing our capabilities, and further advancing our trusted partner status with customers, leading to continued share gain.”
🔸 “At the halfway point of the year, we are well positioned to deliver a great 2026 and build an even brighter future for our company.”
🔹 Revenue: $11.99B (Est. $11.7B) 🟢; +10% YoY
🔹 Adj. EPS: $6.03 (Est. $5.71) 🟢; +13% YoY
🔹 Organic Revenue Growth: 5%
Other Q2 Metrics:
🔹 Organic Revenue Growth: 5%
🔹 GAAP Operating Margin: 17.4%; +50 bps YoY
🔹 Adjusted Operating Margin: 22.8%; +90 bps YoY
🔹 Free Cash Flow: $1.68B
Segment Net Revenue:
🔹 Life Sciences Solutions: $2.8B
🔹 Analytical Instruments: $1.8B
🔹 Specialty Diagnostics: $1.2B
🔹 Laboratory Products and Biopharma Services: $6.7B
Comments:
🔸 “Our end markets continue to strengthen and we're making great progress enhancing our capabilities, and further advancing our trusted partner status with customers, leading to continued share gain.”
🔸 “At the halfway point of the year, we are well positioned to deliver a great 2026 and build an even brighter future for our company.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。